On Friday, ATAI Life Sciences N.V (NASDAQ: ATAI) opened lower -6.37% from the last session, before settling in for the closing price of $1.57. Price fluctuations for ATAI have ranged from $1.03 to $2.85 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -13.20% over the last five years. Company’s average yearly earnings per share was noted 24.17% at the time writing. With a float of $135.18 million, this company’s outstanding shares have now reached $167.82 million.
The firm has a total of 54 workers. Let’s measure their productivity. In terms of profitability, gross margin is 46.43%, operating margin of -33305.52%, and the pretax margin is -48272.08%.
ATAI Life Sciences N.V (ATAI) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of ATAI Life Sciences N.V is 32.31%, while institutional ownership is 7.34%. The most recent insider transaction that took place on Mar 21 ’25, was worth 65,560. In this transaction Chief Business Officer of this company sold 48,563 shares at a rate of $1.35, taking the stock ownership to the 115,636 shares. Before that another transaction happened on Mar 21 ’25, when Company’s Chief Medical Officer sold 11,563 for $1.35, making the entire transaction worth $15,610. This insider now owns 8,437 shares in total.
ATAI Life Sciences N.V (ATAI) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 24.17% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 17.72% during the next five years compared to 18.62% growth over the previous five years of trading.
ATAI Life Sciences N.V (NASDAQ: ATAI) Trading Performance Indicators
Check out the current performance indicators for ATAI Life Sciences N.V (ATAI). In the past quarter, the stock posted a quick ratio of 5.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 883.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.80, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.79 in one year’s time.
Technical Analysis of ATAI Life Sciences N.V (ATAI)
Analysing the last 5-days average volume posted by the [ATAI Life Sciences N.V, ATAI], we can find that recorded value of 1.89 million was lower than the volume posted last year of 2.91 million. As of the previous 9 days, the stock’s Stochastic %D was 52.53%. Additionally, its Average True Range was 0.15.
During the past 100 days, ATAI Life Sciences N.V’s (ATAI) raw stochastic average was set at 27.72%, which indicates a significant decrease from 44.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 80.48% in the past 14 days, which was lower than the 106.01% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.7071, while its 200-day Moving Average is $1.4362. Now, the first resistance to watch is $1.5400. This is followed by the second major resistance level at $1.6100. The third major resistance level sits at $1.6500. If the price goes on to break the first support level at $1.4300, it is likely to go to the next support level at $1.3900. Now, if the price goes above the second support level, the third support stands at $1.3200.
ATAI Life Sciences N.V (NASDAQ: ATAI) Key Stats
There are currently 198,306K shares outstanding in the company with a market cap of 291.51 million. Presently, the company’s annual sales total 310 K according to its annual income of -149,270 K. Last quarter, the company’s sales amounted to 40 K and its income totaled -26,290 K.
